Drug Database · Clinicians

Carisoprodol + Paracetamol

Also known as: acetaminophen (US name, for paracetamol)

Brands (1) LagaflexShow all

Muscle relaxant / analgesic PH FDA category
Fixed-dose combination.

S2 · Dangerous drug — PDEA S2 license required; see prescription rules belowRx · Prescription drug1 PH product

1971 Convention Schedule IV; Philippine Schedule 4; PDEA S-2 license required. Oral FDA-registered Philippine Schedule 4 preparations: ordinary prescription in triplicate (BR 1 s.2014 Sec. 4(4)(a)); other forms: DOH Special Prescription Form (yellow) (Sec. 31(2)). No refill; up to a 30-day supply, 60 days for epilepsy and dystonia (Sec. 31(6)(d)-(e)). Until June 30, 2027, S-2 licensed practitioners may use an ordinary prescription in triplicate instead of the special form (one dangerous drug per prescription, "NO REFILL", up to 30 days; 60 days for Philippine Schedule 4 drugs in epilepsy and dystonia) (BR 10 s.2025, extended by BR 5 s.2026).; Newly listed: the DDB list dates its 1971 Schedule IV entry 6 December 2025; UN scope changes are adopted under BR 1 s.2020. BR 1 s.2014 Sec. 4(2)(a) lets the Board exempt a Schedule 4/5 preparation from specific controls only if it is non-parenteral, contains one dangerous drug, the drug cannot be readily recovered, and the exemption serves a medical purpose; no exemption is listed for this combination. Source: DDB, Updated Lists of Scheduled Controlled Substances (as of 20 July 2026); Republic Act No. 9165, Comprehensive Dangerous Drugs Act of 2002; DDB Board Regulation No. 3, s. 2020 (CBD drug products; defines Philippine Schedules 1-4); DDB Board Regulation No. 1, s. 2014 (amending BR 3 s. 2003: licensing, prescriptions, exemptions); DDB Board Regulation No. 1, s. 2020 (immediate adoption of UN scope-of-control changes); DDB Board Regulation No. 10, s. 2025 (temporary authorization of ordinary prescriptions for dangerous drugs); DDB Board Regulation No. 5, s. 2026 (ordinary prescriptions for dangerous drugs extended to June 30, 2027).

Dispensing: Prescription (Rx) · Dangerous drug (S2) Last updated: Audience: Licensed health professionals
US label not yet available for this generic. Check the Philippine package insert (linked in the products table where the FDA has published one).

Component information

No US or EU label exists for this exact combination, so information is shown for each component.

  • carisoprodol no separate page
  • Use: Uses temporarily relieves minor aches and pains due to: the common cold headache backache minor pain of arthritis toothache muscular aches premenstrual and menstrual cramps temporarily reduces fever US FDA label

Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney dosing for each component (single-agent) is shown under Component information.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosage forms

Philippines

  • Tablet: 300 mg/250 mg

Registered products in the Philippines

1 product registered with the Food and Drug Administration (FDA) Philippines list Carisoprodol + Paracetamol as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

Philippine FDA-registered products for Carisoprodol + Paracetamol
Package insert
LagaflexCarisoprodol + Paracetamol
300 mg / 250 mg Tablet
Rx
—
Trader: Bio-strata Pharmaceuticals, Inc.
DR-XY814
Feb 1, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .